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Abstract  1 
 2 
Background: - Management of type 2 diabetes remains a challenge in Africa. The objective of 3 
this study was to evaluate the prevalence and predictors of poor glycemic control in patients 4 
with type 2 diabetes living in sub-Saharan. 5 
Patients and methods: - This was a cross-sectional study involving 1267 people (61% 6 
women) with type 2 diabetes (mean age 58 years) recruited across health facilities in 7 
Cameroon and Guinea. Predictors of poor glycemic control (HbA1c ≥7.0% (53 mmol/mol)) 8 
were investigated via logistic regressions. 9 
Results: - The mean body mass index was 27.4 ± 5.8 kg/m2, and 74% of patients had poor 10 
glycemic control. Predictors of poor glycemic control in multivariable regression models were 11 
recruitment in Guinea [odd ratio: 2.91 (95% confidence interval 2.07 to 4.11)], age <65 years 12 
[1.40 (1.04 to 1.88)], diabetes duration ≥3 years [2.36 (1.74 to 3.21)], treatment with: oral 13 
glucose control agents [3.46 (2.28 to 5.26)], insulin alone or with oral glucose control agents 14 
[7.74 (4.70 to 12.74)] and absence of a previous HbA1c measurement in Guinea [2.96 (1.30 to 15 
6.75)].  16 
Conclusion: - Poor control of blood glucose is common in patients with type 2 diabetes in 17 
these two countries. Limited access to HbA1c appears to be a key factor associated with poor 18 
glycemic control in Guinea, and should be addressed by health policies targeting 19 
improvement in the outcomes of diabetes care. 20 
 21 
Keywords: Type 2 diabetes, glycemic control, sub-Saharan Africa 22 
23 
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1. Introduction 1 
 2 
Type 2 diabetes is a common and rapidly growing chronic non-communicable disease 3 
worldwide [1], including in sub-Saharan Africa [2]. The long-term microvascular and 4 
macrovascular complications of diabetes are responsible for significant morbidity and 5 
mortality. The growing population of people in need of care for diabetes is a challenge for 6 
low-income countries where non-communicable diseases are adding to the burden of 7 
communicable diseases [3].  8 
Several large clinical trials have demonstrated  the beneficial effect of glycemic 9 
control on the development of long-term complications of diabetes [4]. Despite this evidence, 10 
a high proportion of patients with diabetes remains poorly controlled [5]. This is the case in 11 
Africa where a large number of people with diabetes do not reach the recommended HbA1c 12 
targets [6]. The difficulties to achieve an appropriate glycemic control in developing countries 13 
are likely due to a limited access to adequate health services, poor education level, reduced 14 
access to medical education and a lack of monitoring of glucose control. The magnitude of 15 
poor glycemic control in patients with type 2 diabetes in Africa has not been extensively 16 
investigated, nor have the predictors of poor glycemic control received greater attention in 17 
this setting.  18 
The main aim of this study was to determine the prevalence and investigate the 19 
predictors of poor glycemic control in patients with type 2 diabetes across outpatient diabetes 20 
clinics in Cameroon and Guinea. We specifically investigated whether prior measures of 21 
HbA1c affect subsequent glycemic control.  22 
23 
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2. Population and methods  1 
 2 
2.1 Source of data 3 
Patients with type 2 diabetes included in the current study were recruited and examined as 4 
part of the baseline evaluation of the project "Improving access to HbA1c in sub-Saharan 5 
Africa", which has been described previously [7]. In brief, data were collected over a one year 6 
period between 2009 and 2010 and included demographics, history of diabetes, blood 7 
pressure and anthropometric measurements, fasting blood glucose and glycated haemoglobin 8 
(HbA1c). 9 
 10 
2.2 Study sites and population 11 
Patients were recruited in 10 diabetes management centers including six regional centers in 12 
Cameroon (a Central African country with 18 million inhabitants) and four regional centers in 13 
Guinea (a West African country with 10 million inhabitants). The centres were either 14 
university hospitals (UH) where patients were seen by endocrinologists or regional hospitals 15 
(RH) where patients were seen by general physicians or diabetologists. Prior to the study 16 
"Improving access to HbA1c in sub-Saharan Africa", these centers monitored metabolic 17 
control of patients with fasting capillary blood glucose. The study protocol was approved by 18 
the Ethics Committees of the Ministries of Public Health in Cameroon and Guinea. 19 
Participants were informed of the purpose of the study and signed an informed consent. 20 
Between August 2009 and October 2010, 1349 patients with type 1 or type 2 diabetes were 21 
selected at outpatient visits. The inclusion criteria were: being diagnosed with diabetes since 22 
at least one year and being 16 years of age or older. For the current analyses, patients with 23 
missing data on the duration of diabetes and age were excluded (n = 17), as well as those with 24 
type 1 diabetes (n = 65). Thus, data from 1267 patients with type 2 diabetes were analysed. 25 
 26 
2.3 Measurements and operational definition 27 
In this study, HbA1c was measured in a capillary blood sample by spectrophotometry 28 
using the Biorad ® IN2IT devices [8,9]. A good glycemic control was defined as HbA1c 29 
<7.0% (<53 mmol/mol) [10].  30 
The following data were collected:  country of recruitment, health facility (University 31 
or Regional hospital), gender (Female or Male), age (dichotomized into <65 or ≥65 years), 32 
marital status (married, single), level of education (Illiterate, ≤ High school,  >High school), 33 
employment (employed or unemployed), duration of diabetes (grouped as 1-2 and ≥3 years), 34 
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treatment of diabetes (categorized as diet only, oral glucose control agents alone, insulin alone 1 
or with oral glucose control agents), self-monitoring of blood glucose (yes or no), waist and 2 
hip circumferences. Among the 350 subjects who were treated with insulin, information about 3 
the number of injections per day was available for 262 patients who were grouped as 1 and 2-4 
3 injections per day. The socioeconomic status was based on the employment status and level 5 
of education. The body mass index (BMI) was calculated using Quetelet’s index (weight / 6 
height2) and expressed in kilograms per meters square (kg/m2) and was further dichotomized 7 
into <25 and ≥25 kg/m². 8 
The American Diabetes Association definition of hypertension was applied: i.e. 9 
systolic/diastolic blood pressure ≥ 130/80 mmHg or antihypertensive treatment [10]. The 10 
patients were classified for hypertension status as normal, unknown hypertension, known 11 
hypertension with treatment and known hypertension without treatment.  12 
 13 
2.4 Statistical analysis 14 
Data are presented as mean ± SD or as [median (quartile 1, quartile 3)] for continuous 15 
variables and as count (%) for categorical variables. The Pearson correlation coefficient was 16 
used to measure the continuous association between HbA1c and fasting glucose. Patients 17 
from Cameroon and Guinea were combined for the analysis the predictors of poor glycemic 18 
control. 19 
Predictors with p ≤0.30 in univariable analysis were entered into a multivariable 20 
logistic regression models, and factors associated with poor glycemic control retained from 21 
backward selections. Interaction terms were tested and those significant at p <0.10 were 22 
added to the final model. Odds ratios and 95% confidence intervals were calculated and a 23 
value of p <0.05 was considered statistically significant. The quality of the final model was 24 
verified by the Hosmer and Lemeshow fit test and the area under receiver operating 25 
characteristic curve. Analyses used SAS software (version 9.3, SAS Institute, Cary, NC). 26 
27 
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3. Results  1 
 2 
3.1 Characteristics of the study population 3 
The characteristics of the 1267 patients with type 2 diabetes included in the study are 4 
presented in Table 1; 60% were from Cameroon; 54% were followed in university hospitals; 5 
30% were illiterate. The mean duration of diabetes was 7.6 ± 6.3 years [median 6 years (25th-6 
75th percentiles: 3-10)]. The mean age was 58.4 ± 10.5 years [median 58 years (52- 65)]. They 7 
were mostly treated with an oral oral glucose control agents alone (62% overall, 66% in 8 
Cameroon and 56% in Guinea). Among patients who were receiving insulin, the information 9 
of number of injections per day was available for 262. Most of them (90.1%) had two or three 10 
injections per day. In all 39% of patients reported that they self-monitored their blood 11 
glucose, more frequently in Guinea (42%) than in Cameroon (38%).  Only 21% had had a 12 
previous determination of HbA1c prior to the study. The mean body mass index (BMI) was 13 
27.4 ± 5.8 kg/m², which was significantly higher in Cameroon (28.6 ± 6.2 kg/m²) than in 14 
Guinea (25.5 ± 4.7 kg/m²); p <0.001. Among the 962 subjects (76%) with hypertension, only 15 
42% were on antihypertensive therapy at inclusion. 16 
 17 
3.2  Glycemic and blood pressure control 18 
Among the 1267 patients, 939 (74%) had an HbA1c ≥7.0% (≥53 mmol/mol) of whom 388 19 
(41%) had an HbA1c ≥10.0% (≥86 mmol/mol) (Table 2). The frequency of poor glycemic 20 
control was 74% overall and significantly higher in Guinea (84%) than in Cameroon (68%); 21 
p <0.001. The average HbA1c was 8.9 ± 2.5% (74 ± 4 mmol/mol) and fasting glucose 22 
averaged 9.4 ± 4.3 mmol/L. HbA1c and fasting glucose were significantly and positively 23 
correlated with each other (r = 0.68, p <0.001). A blood pressure below 130 / 80 mmHg was 24 
observed in only 250 subjects (20%) and only 75 (6%) patients had both glycemia and blood 25 
pressure values below the recommended thresholds.  26 
 27 
3.3 Univariable predictors of poor glycemic control 28 
Demographic factors significantly associated with poor glycemic control were: 29 
recruitment in Guinea [odds ratio: 2.52 (95% confidence interval: 1.89 to 3.34)] and age 30 
under 65 years [1.33 (1.01 to 1.75)]. Diabetes was more likely to be poorly controlled among 31 
those with little education [1.53 (1.13 to 2.07)] (Table 2). Compared to the patients with 32 
<high school, those with ≥high school were the most likely to have poor glycemic control 33 
even though this did not reach statistical significance. Clinical and behavioural factors 34 
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associated with poor glycemic control were the presence of high diastolic blood pressure 1 
[1.39 (1.07 to 1.80)], absence of previous measures of HbA1c [1.68 (1.25 to 2.25)], diabetes 2 
duration ≥3 years [2.61 (1.97 to 3.47)], treatment with oral glucose control agents [2.55 (1.75 3 
to 3.72)], insulin alone or with oral glucose control agents [6.25 (3.94 to 9.91)]. Those who 4 
had two or more insulin injections per day had a significantly higher odds ratio of having a 5 
poor glycemic control [OR: 2.98; 95% CI: (1.14 to 7.75)] than those with one injection per 6 
day. Normal weight (BMI <25 kg/m²) was also associated with poor glycemic control [1.43 7 
(1.09 to 1.88)]. 8 
 9 
3.4 Multivariable predictors poor glycemic control 10 
The variables significantly associated with poor glycemic control based on a threshold 11 
of p <0.30 in univariate models, were entered altogether in the same multivariable model. 12 
Then backward selection procedures were applied to retain the final predictors (Table 3). Of 13 
all the interactions terms tested, only the interaction between country and previous 14 
measurement of HbA1c (p = 0.06) was significant and was therefore added to the final model 15 
which included: recruitment in Guinea [2.91 (2.07 to 4.11)], age <65 years [1.40 (1.04 to 16 
1.88)], diabetes duration ≥3 years [2.36 (1.74 to 3.20)], treatment with oral glucose control 17 
agents alone [3.46 (2.28 to 5.26)], insulin alone or with oral glucose control agents [7.74 (4.70 18 
to 12.74)] and no previous measurement of HbA1c in Guinea [2.96 (1.30 to 6.75)]. The level 19 
of education, the body mass index, the diastolic blood pressure and the number of insulin 20 
injections were not significantly related to the glycemic control in the multivariate model. 21 
 The Hosmer and Lemeshow chi-square statistic for the final multivariable model was 22 
1.50 (p = 0.98); and the area under the ROC curve was 73%. 23 
24 
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4. Discussion 1 
This study has revealed that three out of four patients with type 2 diabetes in the 2 
participating centres in two Sub-Sarahan African countries (Cameroon and Guinea), had poor 3 
glycemic control and only 6% were at target control levels for glycemia and blood pressure 4 
values. On average, the diagnosed duration of diabetes was eight years at enrolment in the 5 
study. Recruitment in Guinea, younger age, longer duration of diabetes, treatment with oral 6 
glucose control agents with or without insulin, and lack of previous HbA1c measures were the 7 
main predictors of poor glycemic control.  8 
High frequencies of poor glycemic control for type 2 diabetes, defined by HbA1c 9 
thresholds of 6.5% (48 mmol/mol) or 7.0% (53 mmol/mol), have been reported across regions 10 
around the world. In "The International Diabetes Mellitus Practice Study” (IDMPS) [11], 11 
conducted in low-income countries, the frequency of poor glycemic control in type 2 diabetes 12 
ranged from 63% in Asia to 64% in Eastern Europe and Latin America. In the" Diabcare 13 
Africa study" [6] conducted across six African countries, the prevalence of HbA1c ≥6.5% 14 
(≥48 mmol/mol) was 71%. 15 
  After adjusting for the others variables the level of education was not associated with 16 
poor glycemic control. Our result in terms of level of education was similar to that reported in 17 
Michigan [12]. However, a low level of education was associated with poor glycemic control 18 
in Jordan [13] and in Mexican Americas in the United States [14].  19 
 Our study confirmed that a longer duration of diabetes is significantly associated with 20 
poor glycemic control [15,16], as observed in the natural history of the disease. Furthermore, 21 
among patients with longstanding diabetes, those with normal BMI were more likely to have 22 
poor glycemic control, possibly reflecting the effect of weight loss in the context of poor 23 
glycemic control [17]. We also found young age to be associated with poor glycemic control, 24 
in line with some reports in the literature [18–20] but not all [15,21]. Treatment with oral 25 
glucose lowering agents or insulin was associated with poorer glycemic control, most likely 26 
reflecting the phenomenon of reverse causality, i.e. more intensive treatment being required 27 
by the presence of elevated glycaemia. A poor glycemic control was more frequently 28 
observed among patients who were treated with drugs (oral agents and / or insulin), but more 29 
so in those who were treated with insulin (alone or in combination with oral drugs). Some 30 
studies [22,23] have reported a link between poor glycemic control and treatment with a 31 
combination of oral glucose lowering agents and insulin. These results may reflect a delay in 32 
the introduction of insulin in the treatment of patients with poor glycemic control [4,24] but 33 
also to the intensification of insulin therapy with insufficient insulin doses. 34 
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Affordable access to HbA1c measurements for people with diabetes remain a 1 
challenge in developing countries [25], which may affect the quality of care and explain the 2 
correlation found in our study lack of access to HbA1c and poor glycemic control in Guinea. 3 
Indeed, HbA1c measurement is the cornerstone in strategies for initiating and intensifying 4 
treatments for people with diabetes [26]. Availability of HbA1c has been associated with 5 
improved glycemic control [27], both by positively affecting the attitude of healthcare 6 
providers [28], and improving adherence to treatments in patients. 7 
The cross-sectional nature of this study limits inferences about causality of relationships 8 
between the predictors identified in the study and poor diabetes control in our sample. This 9 
study is also limited by the lack of information on physical activity, psychological status, and 10 
compliance to treatment, other factors that may influence glycemic control and the outcomes 11 
of diabetes care. 12 
In conclusion, the percentage of patients with poor glycemic control is as high in 13 
Cameroon and Guinea as has been reported in a number of other countries. Limited access to 14 
HbA1c monitoring appears to be a contributing factor. These findings suggest that increased 15 
access to an HbA1c test could be an important step in health policies to improve glycemic 16 
control in patients with type 2 diabetes from Sub Sahara Africa. 17 
 18 
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Table 1: Characteristic (mean ± SD or n (%)) of the 1267 type 2 diabetes patients from 1 
Cameroon and Guinea.   2 
 3 
  Total  
(N=1267)  
Cameroon  
(n=766) 
Guinea  
(n=501) 
Age (years) 58.4 (±10.5) 58.7 (±10.7) 57.8 (±10.1) 
Monitoring site: University Hospital 688 (54%) 380 (50%) 308 (61%) 
Women 775 (61%) 461 (60%) 314 (63%) 
Married 881 (70%) 499 (65%) 382 (76%) 
Unemployed 612 (48%) 383 (50%) 229 (46%) 
Level of education       
Illiterate 378 (30%) 162 (21%) 216 (43%) 
≤High school 678 (53%) 500 (65%) 178 (36%) 
>High school 211 (17%) 104 (14%) 107 (21%) 
Treatment of diabetes       
Diet only 130 (10%) 53 (7%) 77 (15%) 
oral glucose control agents alone 787 (62%) 509 (66%) 278 (56%) 
insulin alone or with oral glucose control agents 350 (28%) 204 (27%) 146 (29%) 
Number insulin injections per day (n=262) 1.9 (±0.3) 1.9 (±0.4) 1.9 (±0.3) 
Diabetes duration (years) 7.6 (±6.3) 7.5 (±6.5) 7.8 (±5.9) 
Previous measurement of HbA1c 266 (21%) 232 (30%) 34 (7%) 
Self-monitoring of blood glucose  498 (39%) 289 (38%) 209 (42%) 
Known hypertension 962 (76%) 534 (70%) 428 (85%) 
Hip (cm) 101 (±11.4) 102 (±11.8) 99.6 (±10.7) 
Waist (cm) 94.8 (±13) 96.2 (±14.1) 92.7 (±10.6) 
Body mass index (kg/m²) 27.4 (±5.8) 28.6 (±6.2) 25.6 (±4.7) 
4 
Page 14 of 15
Ac
ce
pte
d M
an
us
cri
pt
 14
Table 2: Odds ratios for factors associated with poor diabetes control (HbA1c ≥7%) in type 2  1 
diabetes patients in Cameroon and Guinea 2 
 3 
 HbA1c < 7% 
 (n=328) 
HbA1c ≥ 7%  
(n=939)  
OR non adjusted 
(95% CI) 
Country      
Cameroon 248 (32%) 518 (68%) Ref - 
Guinea 80 (16%) 421 (84%) 2.52 1.89-3.34 
Monitoring site       
University Hospital 171 (25%) 517 (75%) Ref - 
Regional Hospital 157 (27%) 422 (73%) 0.89 0.69-1.14 
Age        
≥ 65 years 102 (30.0%) 238 (70.0%) Ref - 
< 65 years 226 (24.4%) 701 (75.6%) 1.33 1.01-1.75 
Sex      
Man 138 (28%) 355 (72%) Ref - 
Woman 190 (24%) 584 (75%) 1.19 0.93-1.54 
Marital status (Married)      
No 101 (26%) 285 (74%) Ref - 
Yes 227 (26%) 654 (74%) 1.02 0.78-1.34 
Employment       
Unemployed 169 (28%) 443 (72%) Ref - 
 Employed 159 (24%) 496 (76%) 1.19 0.92-1.53 
Level of education      
Illiterate 78 (20.6%) 300 (79.4%) 1.53 1.13-2.07 
≤High school 193 (28.5%) 485 (71.5%) Ref - 
>High school 57 (27.0%) 154 (73.0%) 1.07 0.76-1.52 
Treatment of diabetes      
Diet only 64 (49.2%) 66 (50.8%) Ref - 
oral glucose control agents alone 217 (27.6%) 570 (72.4%) 2.55 1.75- 3.72 
insulin alone or with oral glucose control agents 47 (13.4%) 303 (86.6%) 6.25 3.94-9.91 
Number injections per day (n=262)       
1 7 (26.9%) 19 (73.1%) Ref - 
2-3 26 (11.0%) 210 (89.0%) 2.98 1.14 - 7.75 
Duration of diabetes      
<1-3 years 114 (41.8%) 159 (58.2%) Ref - 
≥3 years 214 (21.5%) 780 (78.5%) 2.61 1.97-3.47 
Previous measurement of HbA1c       
Yes 91 (34.2%) 175 (65.8%) Ref - 
No 237 (23.7%) 764 (76.3%) 1.68 1.25-2.25 
Self-monitoring of blood glucose      
Yes 132 (26.5%) 366 (73.5%) Ref - 
No 196 (25.5%) 573 (74.5%) 1.05 0.82-1.36 
Body mass index       
≥25 kg/m² 231 (28.3%) 586 (71.7%) Ref - 
<25 kg/m² 97 (21.6%) 353 (78.4%) 1.43 1.09-1.88 
Hypertension      
unknown hypertension 86 (28.2%) 219 (71.8%) Ref - 
known hypertension treated 103 (25.6%) 300 (74.4%) 1.14 0.82-1.59 
known hypertension without treatment 139 (24.9%) 420 (75.1%) 1.19 0.87-1.63 
Blood pressure systolic  ≥130 mmHg                    
No 100 (28.3%) 254 (71.7%) Ref - 
Yes 228 (25.0%) 685 (75.0%) 1.18 0.89-1.56 
Blood pressure  diastolic  ≥80 mmHg              
No 135 (30.1%) 314 (69.9%) Ref - 
Yes 193 (23.6%) 625 (76.4%) 1.39 1.07-1.80 
4 
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Table 3: Odds ratios (95% confidence intervals) of factors associated independently with 1 
poor glycemic control (HbA1c≥7%) in type 2 diabetes patients in Cameroon and Guinea   2 
 3 
 OR (95% CI) without 
interaction term 
OR (95% CI) with 
interaction term 
Country (Guinea) 2.62 (1.90 -3.61) 2.91 (2.07 - 4.11) 
Age (<65 years) 1.39 (1.03 -1.88) 1.40 (1.04 - 1.88) 
Duration of diabetes (≥3 years) 2.36 (1.74 -3.20) 2.36 (1.74 - 3.21) 
Treatment of diabetes     
oral glucose control agents alone 3.38 (2.23 -5.12) 3.46 (2.28 - 5.26) 
insulin alone or with oral glucose control agents 7.60 (4.62 -12.48) 7.74 (4.70 - 12.74) 
Previous measurement of HbA1c (none) 1.43 (1.04 -1.98)   
No previous measurement of HbA1c in Guinea   2.96 (1.30 - 6.75) 
No previous measurement of HbA1c in Cameroon   1.28  (0.91 - 1.81) 
 4 
 5 
